Legal & General Group
MACK

Legal & General Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Legal & General Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-980
Closed -$14.5K – 3583
2024
Q1 		$14.5K Sell
980
-306
-24% -$4.3K ﹤0.01% 3104
2023
Q4 		$17.2K Hold
1,286
– – ﹤0.01% 3088
2023
Q3 		$15.9K Hold
1,286
– – ﹤0.01% 3120
2023
Q2 		$15.8K Buy
+1,286
New +$16.1K ﹤0.01% 3211
2018
Q2 		– Sell
-3,432
Closed -$22K – 3473
2018
Q1 		$22K Sell
3,432
-1,314
-28% -$10.9K ﹤0.01% 3095
2017
Q4 		$39K Hold
4,746
– – ﹤0.01% 2955
2017
Q3 		$54K Buy
4,746
+262
+6% +$2.75K ﹤0.01% 2895
2017
Q2 		$43K Hold
4,484
– – ﹤0.01% 2951
2017
Q1 		$108K Sell
4,484
-192
-4% -$4.8K ﹤0.01% 2500
2016
Q4 		$151K Buy
4,676
+1,464
+46% +$62.4K ﹤0.01% 2341
2016
Q3 		$159K Sell
3,212
-190
-6% -$7.89K ﹤0.01% 2091
2016
Q2 		$144K Hold
3,402
– – ﹤0.01% 1905
2016
Q1 		$226K Buy
3,402
+983
+41% +$51.3K ﹤0.01% 1694
2015
Q4 		$151K Hold
2,419
– – ﹤0.01% 1871
2015
Q3 		$159K Buy
2,419
+473
+24% +$38.6K ﹤0.01% 1810
2015
Q2 		$185K Hold
1,946
– – ﹤0.01% 1785
2015
Q1 		$182K Hold
1,946
– – ﹤0.01% 1721
2014
Q4 		$173K Sell
1,946
-68
-3% -$4.95K ﹤0.01% 1650
2014
Q3 		$139K Buy
+2,014
New +$108K ﹤0.01% 1697

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Legal & General Group's MACK Position: Q2 2024 in Review

Legal & General Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 980 shares — an estimated $14.5K sold.

Legal & General Group first reported a position in MACK in Q3 2014 and held it in 19 quarters. The position peaked at $226K in Q1 2016. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Legal & General Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 980 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $14.5K.
  • Legal & General Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 19 quarters.
  • Legal & General Group's Merrimack Pharmaceuticals, Inc. position peaked at $226K in Q1 2016.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.